Northern Trust’s Protalix BioTherapeutics PLX Stock Holding History

Northern Trust’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.92M	Buy	885,448 +19,740	+2%	+$49K	﹤0.01%	2999
2025 Q4	$1.56M	Sell	865,708 -36,751	-4%	-$75.1K	﹤0.01%	3137
2025 Q3	$2M	Sell	902,459 -177,264	-16%	-$289K	﹤0.01%	3034
2025 Q2	$1.6M	Buy	1,079,723 +394,965	+58%	+$808K	﹤0.01%	3119
2025 Q1	$1.75M	Sell	684,758 -46,984	-6%	-$112K	﹤0.01%	2988
2024 Q4	$1.38M	Buy	731,742 +679,451	+1,299%	+$961K	﹤0.01%	3234
2024 Q3	$53.3K	Sell	52,291 -370,922	-88%	-$390K	﹤0.01%	4191
2024 Q2	$495K	Sell	423,213 -34,932	-8%	-$41.3K	﹤0.01%	3514
2024 Q1	$577K	Sell	458,145 -36,092	-7%	-$53.9K	﹤0.01%	3518
2023 Q4	$880K	Buy	494,237 +87,766	+22%	+$136K	﹤0.01%	3354
2023 Q3	$675K	Buy	406,471 +43,558	+12%	+$78.2K	﹤0.01%	3430
2023 Q2	$726K	Buy	+362,913	New	+$865K	﹤0.01%	3448
2019 Q4	–	Sell	-3,081	Closed	-$6K	–	4286
2019 Q3	$6K	Hold	3,081	–	–	﹤0.01%	4212
2019 Q2	$15K	Hold	3,081	–	–	﹤0.01%	4189
2019 Q1	$14K	Hold	3,081	–	–	﹤0.01%	4151
2018 Q4	$10K	Sell	3,081 -120	-4%	-$570	﹤0.01%	4200
2018 Q3	$23K	Hold	3,201	–	–	﹤0.01%	4215
2018 Q2	$14K	Sell	3,201 -23	-0.7%	-$102	﹤0.01%	4238
2018 Q1	$17K	Hold	3,224	–	–	﹤0.01%	4178
2017 Q4	$22K	Buy	3,224 +246	+8%	+$1.66K	﹤0.01%	4151
2017 Q3	$17K	Hold	2,978	–	–	﹤0.01%	4169
2017 Q2	$25K	Hold	2,978	–	–	﹤0.01%	4164
2017 Q1	$40K	Sell	2,978 -192	-6%	-$1.73K	﹤0.01%	4075
2016 Q4	$14K	Buy	3,170 +60	+2%	+$268	﹤0.01%	4120
2016 Q3	$18K	Hold	3,110	–	–	﹤0.01%	4112
2016 Q2	$20K	Hold	3,110	–	–	﹤0.01%	4119
2016 Q1	$26K	Hold	3,110	–	–	﹤0.01%	4107
2015 Q4	$31K	Hold	3,110	–	–	﹤0.01%	4122
2015 Q3	$36K	Hold	3,110	–	–	﹤0.01%	4129
2015 Q2	$60K	Buy	3,110 +15	+0.5%	+$311	﹤0.01%	4043
2015 Q1	$55K	Sell	3,095 -543	-15%	-$10.6K	﹤0.01%	4138
2014 Q4	$66K	Buy	3,638 +36	+1%	+$773	﹤0.01%	4057
2014 Q3	$87K	Buy	3,602 +56	+2%	+$1.61K	﹤0.01%	4046
2014 Q2	$130K	Hold	3,546	–	–	﹤0.01%	3962
2014 Q1	$162K	Buy	3,546 +230	+7%	+$10.7K	﹤0.01%	3839
2013 Q4	$129K	Sell	3,316 -1,235	-27%	-$52K	﹤0.01%	3819
2013 Q3	$206K	Sell	4,551 -3,618	-44%	-$186K	﹤0.01%	3656
2013 Q2	$401K	Buy	+8,169	New	+$433K	﹤0.01%	3496

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust's PLX Position: Q1 2026 in Review

Northern Trust increased its Protalix BioTherapeutics (PLX) stake by 2.3% in Q1 2026, buying an estimated $49K and bringing the position to 885,448 shares worth $1.92M. The position accounts for ﹤0.01% of the portfolio, ranked #2999.

Northern Trust first reported a position in PLX in Q2 2013 and has held it in 38 quarters since. The position peaked at $2M in Q3 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

Northern Trust held 885,448 shares of Protalix BioTherapeutics worth $1.92M as of Q1 2026.
Northern Trust bought 19,740 Protalix BioTherapeutics shares in Q1 2026, an estimated $49K.
Protalix BioTherapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2999 holding.
Northern Trust first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 38 quarters since.
Northern Trust's Protalix BioTherapeutics position peaked at $2M in Q3 2025.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.